NOVEL SCHEDULES FOR ADMINISTERING COMBINATION THERAPIES USEFUL FOR TREATING PERSONS AFFLICTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV)

摘要

The present invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in humans, including three or four active principles selected as: a nucleoside reverse transcriptase inhibitor (NRTI) selected from lamivudine and emtricitabine; a nucleoside or nucleotide reverse transcriptase inhibitor (NRTI) selected from didanosine, abacavir and tenofovir; and the combination of a boosted or unboosted protease inhibitor (PI) selected from lopinavir, fosamprenavir, atazanavir and darunavir; or an non-nucleoside reverse transcriptase inhibitor (NNRTI) selected from efavirenz and etravirine; or an integrase inhibitor; for daily administration to said human being one to four days per week.

主权项

1. A method for treatment of HIV in a human being infected with this virus by administration once in a 24 hour period and the administration being repeated no more than four times during a week to said human being of a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in a human being comprising three or four active principles selected as being:
one nucleoside inhibitor of reverse transcriptase (NRTI) selected from lamivudine and emtricitabine; one nucleoside or nucleotide inhibitor of reverse transcriptase (NRTI) selected from didanosine, abacavir and tenofovir; and one or two of the following:
(1) a combination of ritonavir with a protease inhibitor (PI) selected from lopinavir, fosamprenavir, atazanavir and darunavir;(2) a non-nucleoside inhibitor of reverse transcriptase (NNIRT) selected from efavirenz and etravirine; or(3) an integrase inhibitor.